News round-up for 4-8 September by DDW Digital Content Editor Diana Spencer.
This week we have seen the vital importance of collaboration to the successful development and discovery of novel therapeutics, exemplified by the new deal agreed by the UK and EU to admit the UK back into Horizon Europe, the largest collaborative research programme in the world.
The top stories:
UK joins Horizon Europe in “huge win” for research community
Following lengthy negotiations, the UK government has announced that the UK will be participating as a fully associated member of Horizon Europe for the remaining life of the programme to 2027.
Intelligent OMICS and Janssen enter AI research collaboration
AI drug discovery company Intelligent OMICS and Janssen Research & Development have agreed a target discovery collaboration to evaluate novel biological targets for the treatment of haematological cancers.
Optibrium acquires BioPharmics
AI drug discovery company Optibrium has acquired 3D drug design specialist BioPharmics. BioPharmics’ CEO, Dr Ajay Jain, and Director of Applied Science, Dr Ann Cleves, will join the Optibrium team.
Antibody development drives high-value biotech deals
The development of antibodies and associated technologies continues to drive high-value deals, according to a recent report in Nature.
CRISPR collaboration will advance cell therapy for muscular dystrophy
A new licensing agreement between Vita Therapeutics and MilliporeSigma (the US and Canada Life Science business of Merck) will see Vita leverage MilliporeSigma’s foundational CRISPR patents to advance its preclinical asset VTA-100 for limb-girdle muscular dystrophy (LGMD2A).
